Notably, TP53 mutations have previously been found to predict poor survival in CHOP‐treated patients with GCB DLBCL and in R‐CHOP‐treated patients with either GCB or ABC DLBCL [23, 24]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.